The Pleco innovation is in delivering Plecoid™ therapy.
It entails the exploitation of cutting edge medical science and is subject to continued investigation in the laboratories affiliated with Pleco. Plecoid™ therapy is being shown to deliver considerably improved outlook for AML patients over and above the current best standard of care.
The product development programme for delivering Plecoid™ therapy as a commercial proposition is taking place within Pleco. The first product proposition uses a balanced and optimised combination of chelating agents with preference given to existing approved and proven agents.


We have developed a diverse pipeline with several combination products currently in preclinical development.